Valuation: Lord Global Corporation

Market Cap 5.28M 4.52M 4.22M 3.87M 7.27M 505M 7.42M 50.05M 19.51M 253M 19.83M 19.4M 839M P/E 2018 *
-
P/E 2019 -0.6x
Enterprise Value 5.89M 5.04M 4.7M 4.32M 8.11M 564M 8.27M 55.81M 21.76M 282M 22.11M 21.63M 935M EV / Sales 2018
1,290x
EV / Sales 2019 1,135x
Free-Float
25.63%
Yield 2018 *
-
Yield 2019 -
Current year 0
Extreme 0.0002
0
1 year 0
Extreme 0.0002
0
3 years 0
Extreme 0.0001
0
5 years 0
Extreme 0.0001
0.6
10 years 0
Extreme 0
200,000
Manager TitleAgeSince
Chief Executive Officer 36 24/01/2020
Director TitleAgeSince
Chairman 36 24/01/2020
Change 5-day change 1-year change 3-year change Capi.($)
+100.00%-.--%-.--%-.--% 372
-3.82%+2.56%-26.86%-30.16% 11.89B
-0.45%-2.77%+105.36%+128.93% 9.7B
+0.78%+3.62%-21.55%+43.69% 8.06B
+0.83%-9.74%-44.35%+28.71% 4.73B
+0.45%-12.08%+1.49%-3.48% 4.4B
+2.76%-4.81%-42.19%-47.81% 4.12B
+0.65%-0.34%+88.08%+82.70% 3.45B
+1.27%-9.89%-7.23%-19.28% 3.27B
+1.42%-2.72%-49.82%-20.56% 2.98B
Average +10.39%-0.64%+0.29%+16.28% 5.26B
Weighted average by Cap. -0.30%+1.23%+5.39%+25.26%

Financials

2018 2019
Net sales 2.83K 2.42K 2.26K 2.07K 3.89K 271K 3.97K 26.79K 10.44K 136K 10.61K 10.38K 449K 888 760.31 709.38 650.92 1.22K 84.97K 1.25K 8.42K 3.28K 42.58K 3.33K 3.26K 141K
Net income -6.43M -5.51M -5.14M -4.72M -8.86M -616M -9.04M -60.97M -23.77M -308M -24.16M -23.63M -1.02B -491K -420K -392K -360K -676K -46.95M -689K -4.65M -1.81M -23.53M -1.84M -1.8M -77.9M
Net Debt 651K 557K 520K 477K 896K 62.24M 914K 6.16M 2.4M 31.19M 2.44M 2.39M 103M 608K 520K 485K 445K 837K 58.15M 854K 5.76M 2.25M 29.14M 2.28M 2.23M 96.48M
Logo Lord Global Corporation
27 Health Holdings Corp., formerly Lord Global Corporation, is focused on the business development of its 27Health Inc. subsidiary. 27Health Inc. is focused on financing and marketing, healthcare-related products. The Company distributes the Virolens product in Asia, Australia, New Zealand and other Oceania countries. The Virolens system is a COVID-19 screening device based on microscopic holographic imaging and artificial intelligence (AI) software technology. It uses a digital camera attached to a microscope to analyze saliva samples, with the data run through a computer that is trained to identify the virus from other cells, delivering a result in just 20 seconds. The Virolens system was trained to recognize the COVID-19 virus particles in saliva using a range of samples of COVID-19 virus provided by virologists working on the virus at the University of Bristol.
Employees
-
  1. Stock Market
  2. Stocks
  3. LRDG Stock